Survodutide
Dual GLP-1 / glucagon receptor agonist in development for obesity and NASH-related endpoints.
Overview
Emerging trial asset; compare to other dual/triple agonists only in clinical context.
What it is
Synthetic dual incretin/glucagon peptide agonist.
Mechanism (high level)
Dual agonism with metabolic and GI effects typical of the class in trials.
Quick facts
- Dosage
- Trial-specific
- Route
- Subcutaneous
- Cycle
- Per protocol
- Storage
- Per sponsor
Research indications
- Obesity and liver-adjacent metabolic trials
Research protocols (education)
Education-first logging template
Use PepTok to track adherence and notes; any protocol must be directed by a qualified clinician.
Interactions
Often avoided with
- Unsupervised poly-incretin use
Often combined with
- Hepatic monitoring when clinically indicated
Peptides discussed online are not substitutes for diagnosis or prescriptions.
Side effects & safety
- GI adverse events; contraindications per trial criteria.
Regulatory notes
- Investigational; availability limited to trials.
FAQ
Is this a prescription?
PepTok does not provide prescriptions; it is for logging and education.
Related in catalog
Track in app
Save favorites, compare protocols, and track over time
PepTok gives you structure: stacks, reminders, notes, and progress snapshots in one place.
Educational content only. This material is not medical advice. Verify legality, sourcing, and dosing with a qualified professional.